Thomas H. Tranah

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Vishal Patel, Sunjae Lee, Mark McPhail et al. · Journal of Hepatology · 2021 · 221 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

Thomas H. Tranah, María Pilar Ballester, Juan Antonio Carbonell‐Asins et al. · Journal of Hepatology · 2022 · 121 citations · Full text

Medicine, Internal Medicine, Frailty +16

Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate

Audrey Dooley, Shiwen Xu, N. Aden et al. · Lara D. Veeken · 2010 · 69 citations · Full text

Veterinary Medicine, Cell Biology, Pathobiology +17

Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all‐cause admissions in patients on the liver transplant waiting list

Shayon Salehi, Thomas H. Tranah, Samuel Lim et al. · Alimentary Pharmacology & Therapeutics · 2019 · 61 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

María Pilar Ballester, Thomas H. Tranah, Lorenz Balcar et al. · Journal of Hepatology · 2023 · 52 citations · Full text

Medicine, Internal Medicine, Hepatology +16